Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s

This article was originally published in The Pink Sheet Daily

Executive Summary

Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.

You may also be interested in...



Tysabri Clears FDA For Moderate To Severe Crohn’s Disease

Natalizumab will be available for patients with Crohn’s disease by the end of February, Biogen Idec/Elan say.

Tysabri Clears FDA For Moderate To Severe Crohn’s Disease

Natalizumab will be available for patients with Crohn’s disease by the end of February, Biogen Idec/Elan say.

UCB’s Cimzia Rejected For Crohn’s By EMEA Committee

Group also refused to recommend Biogen/Elan’s Tysabri for the disease on appeal.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066333

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel